EntreMed Reports Third Quarter 2010 EPS Loss Of ($0.24)

The Company reported a net loss for the third quarter of 2010 of ($2.1 million), or ($0.24) per share. This compares to a reported net income of approximately $85,000 for the same period last year. Reported net loss for the first nine months of 2010 was ($9.2 million), or ($1.09) per share as compared to ($6.5 million) or ($0.91) per share for 2009. At September 30, 2009, the Company accrued and recorded estimated royalty revenue from sales of Thalomid® of approximately $3.3 million. For 2010, royalty revenues will be recorded when they are received, which we expect to occur in the fourth quarter of 2010 and first quarter of 2011.